查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1620846

色素性视网膜炎市场：按类型、产品、最终用途分类 - 2025-2030 年全球预测

Retinitis Pigmentosa Market by Type (Autosomal Dominant Retinitis Pigmentosa, Autosomal Recessive Retinitis Pigmentosa, X-linked Retinitis Pigmentosa), Offering (Diagnosis, Treatment), End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年色素性视网膜炎市值为98.5亿美元，预计到2024年将达到106.6亿美元，复合年增长率为9.02%，预计到2030年将达到180.4亿美元。

色素性视网膜炎（RP）是一组罕见的遗传性疾病，其特征是视网膜细胞的破坏和丧失，通常导致视力障碍和失明。该市场包括治疗药物、辅助技术、基因测试以及用于该疾病管理和诊断的咨询服务。该领域取得进展的需要源于对有效治疗方法的需要，因为目前的治疗方法主要是姑息性的。应用范围从基因治疗和视网膜植入等药物干预到技术先进的视觉辅助工具。最终用途范围包括积极参与这些解决方案部署和开发的医院、眼科诊所和研究机构。

主要市场统计
基准年[2023] 98.5亿美元
预计年份 [2024] 106.6亿美元
预测年份 [2030] 180.4亿美元
复合年增长率（%） 9.02%

影响 RP 市场的主要成长要素包括由于诊断能力的提高、生物技术的进步以及基因研究投资的增加而导致的盛行率增加。创新治疗方法的发展，例如基于 CRISPR 的基因编辑和新型药物输送系统，提供了巨大的潜在机会。企业应专注于策略伙伴关係和协作研究，以加快研究速度并扩大产品平臺。然而，市场成长面临着治疗成本高、认识有限和严格的监管障碍等挑战，特别是在基因治疗方面。

成熟的研究和开发创新领域包括基因治疗、干细胞治疗和穿戴式助视器的开发。这些领域的努力可以带来对市场状况产生重大影响的突破。这些努力可能不仅有助于开发更好的治疗方法，而且有助于增强辅助技术，提高患者的生活品质。

儘管 RP 市场高度专业且有些分散，但对研发和技术的密集投资可以创造巨大的成长空间。设计加强患者就诊的政策，结合提高意识的教育宣传活动，可以缓解现有的限制，进一步扩大市场机会，并促进永续的业务成长。

市场动态：快速发展的视网膜色素变性市场的关键市场洞察

供需的动态交互作用正在改变色素性视网膜炎市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 影响视网膜的罕见眼科疾病的全球盛行率不断上升
    • 越来越重视基因治疗和个人化医疗
  • 市场限制因素
    • 色素性视网膜炎必要治疗的可近性和可负担性
  • 市场机会
    • 政府支持核准新开发的治疗色素性视网膜炎的药物
    • 视网膜色素变性治疗和诊断的持续进展
  • 市场挑战
    • 对疾病缺乏认识与误诊

波特的五力：驾驭视网膜色素变性市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解视网膜色素变性市场的外部影响

外部宏观环境因素在塑造视网膜色素变性市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解色素性视网膜炎市场的竞争格局

色素性视网膜炎市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵视网膜色素变性市场供应商的绩效评估

FPNV 定位矩阵是评估视网膜色素变性市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製视网膜色素变性市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对视网膜色素变性市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开发：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球影响视网膜的罕见眼科疾病率不断上升
      • 越来越重视基因治疗和个人化医疗
    • 抑制因素
      • 色素性视网膜炎所需治疗的可近性和可负担性
    • 机会
      • 政府支持核准新开发的治疗色素性视网膜炎的药物
      • 治疗和诊断色素性视网膜炎的持续进步
    • 任务
      • 对疾病缺乏认识与误诊
  • 市场区隔分析
    • 类型：体染色体显性遗传性色素性视网膜炎导致色素性视网膜炎病例迅速增加
    • 最终用途：色素性视网膜炎的专科诊所治疗和管理的利用演变
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章色素性视网膜炎市场：依类型

  • 体染色体显性遗传性视网膜色素变性
  • 体染色体隐性遗传色素性视网膜炎
  • X连锁色素性视网膜炎

第七章视网膜色素变性市场：透过提供

  • 诊断
  • 治疗

第 8 章色素性视网膜炎市场：依最终用途

  • 居家护理
  • 医院
  • 专科诊所

第九章美洲视网膜色素变性市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太视网膜色素变性市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲视网膜色素变性市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • jCyte 的 jCell 疗法进入色素性视网膜炎的 3 期试验
    • 杨森从 Meira GTx 获得开创性 XLRP 基因疗法的权利，以加速视网膜疾病的进展
    • RD 基金会支持 NVAsc 视网膜治疗的突破性进展
  • 战略分析和建议

公司名单

  • 4D Molecular Therapeutics, Inc.
  • Astellas Pharma Inc.
  • Beacon Therapeutics Limited
  • BIOGEN INC.
  • Clino Corporation
  • Coave Therapeutics SA
  • Editas Medicine, Inc.
  • GENSIGHT BIOLOGICS
  • Genethon
  • Johnson & Johnson Services, Inc.
  • MeiraGTx Holdings PLC
  • Mimetogen Pharmaceuticals
  • Nacuity Pharmaceuticals, Inc.
  • Novartis AG
  • Orphagen Pharmaceuticals, Inc.
  • Oxford Biomedica PLC
  • Precision BioSciences, Inc.
  • ProQR Therapeutics NV
  • Sanofi SA
  • Santen Pharmaceutical Co., Ltd.
  • Spark Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • The Wyanoke Group
Product Code: MRR-7A1CEDCFE674

The Retinitis Pigmentosa Market was valued at USD 9.85 billion in 2023, expected to reach USD 10.66 billion in 2024, and is projected to grow at a CAGR of 9.02%, to USD 18.04 billion by 2030.

Retinitis Pigmentosa (RP) is a group of rare genetic disorders characterized by the breakdown and loss of cells in the retina, which often leads to vision impairment and blindness. The market scope encompasses therapeutics, assistive technologies, and genetic testing and counseling services aimed at managing and diagnosing the condition. The necessity of advancements in this field stems from the demand for effective treatments, as current therapies are primarily palliative. The application scope spans from pharmacological interventions such as gene therapies and retinal implants to technologically advanced visual aids. The end-use scope includes hospitals, eye care clinics, and research institutions that are actively involved in deploying and developing these solutions.

KEY MARKET STATISTICS
Base Year [2023] USD 9.85 billion
Estimated Year [2024] USD 10.66 billion
Forecast Year [2030] USD 18.04 billion
CAGR (%) 9.02%

Key growth factors influencing the RP market include increasing prevalence rates due to better diagnostic capabilities, advancements in biotechnology, and rising investment in genetic research. The development of innovative treatments like CRISPR-based gene editing and novel drug delivery systems offers significant potential opportunities. Companies should focus on strategic partnerships and collaborations to accelerate research and expand their product pipelines. However, market growth faces challenges such as high treatment costs, limited awareness, and stringent regulatory hurdles, especially concerning gene therapies.

Innovative areas poised for research and development include gene therapy, stem cell therapy, and development of wearable visual aids. Engaging in these areas may lead to breakthroughs that significantly impact the market landscape. Such endeavors are likely to find traction not only in developing better therapeutic solutions but also in enhancing assistive technologies that improve the quality of life for patients.

While the RP market is highly specialized and somewhat fragmented, focused investment in R&D and technology can provide significant room for growth. Crafting policies that bolster patient access, coupled with educational campaigns to increase awareness, can mitigate existing limitations, further expanding market opportunities and contributing towards sustainable business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Retinitis Pigmentosa Market

The Retinitis Pigmentosa Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of rare eye diseases affecting retina worldwide
    • Growing emphasis on genetic therapies and personalized medicine
  • Market Restraints
    • Accessibility and affordability of treatments required for retinitis pigmentosa
  • Market Opportunities
    • Supportive government approvals for newly developed drugs to treat retinitis pigmentosa
    • Ongoing treatment and diagnostics advancements to treat retinitis pigmentosa
  • Market Challenges
    • Lack of awareness and misdiagnosis of the condition

Porter's Five Forces: A Strategic Tool for Navigating the Retinitis Pigmentosa Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Retinitis Pigmentosa Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Retinitis Pigmentosa Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Retinitis Pigmentosa Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Retinitis Pigmentosa Market

A detailed market share analysis in the Retinitis Pigmentosa Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Retinitis Pigmentosa Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Retinitis Pigmentosa Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Retinitis Pigmentosa Market

A strategic analysis of the Retinitis Pigmentosa Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Retinitis Pigmentosa Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Astellas Pharma Inc., Beacon Therapeutics Limited, BIOGEN INC., Clino Corporation, Coave Therapeutics SA, Editas Medicine, Inc., GENSIGHT BIOLOGICS, Genethon, Johnson & Johnson Services, Inc., MeiraGTx Holdings PLC, Mimetogen Pharmaceuticals, Nacuity Pharmaceuticals, Inc., Novartis AG, Orphagen Pharmaceuticals, Inc., Oxford Biomedica PLC, Precision BioSciences, Inc., ProQR Therapeutics N.V., Sanofi S.A., Santen Pharmaceutical Co., Ltd., Spark Therapeutics, Inc., Sun Pharmaceutical Industries Ltd., and The Wyanoke Group.

Market Segmentation & Coverage

This research report categorizes the Retinitis Pigmentosa Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Autosomal Dominant Retinitis Pigmentosa, Autosomal Recessive Retinitis Pigmentosa, and X-linked Retinitis Pigmentosa.
  • Based on Offering, market is studied across Diagnosis and Treatment.
  • Based on End-use, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of rare eye diseases affecting retina worldwide
      • 5.1.1.2. Growing emphasis on genetic therapies and personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Accessibility and affordability of treatments required for retinitis pigmentosa
    • 5.1.3. Opportunities
      • 5.1.3.1. Supportive government approvals for newly developed drugs to treat retinitis pigmentosa
      • 5.1.3.2. Ongoing treatment and diagnostics advancements to treat retinitis pigmentosa
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness and misdiagnosis of the condition
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Burgeoning cases of retinitis pigmentosa due to autosomal dominant retinitis pigmentosa
    • 5.2.2. End-use: Evolving utilization of specialty clinics for the treatment and management of retinitis pigmentosa
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Retinitis Pigmentosa Market, by Type

  • 6.1. Introduction
  • 6.2. Autosomal Dominant Retinitis Pigmentosa
  • 6.3. Autosomal Recessive Retinitis Pigmentosa
  • 6.4. X-linked Retinitis Pigmentosa

7. Retinitis Pigmentosa Market, by Offering

  • 7.1. Introduction
  • 7.2. Diagnosis
  • 7.3. Treatment

8. Retinitis Pigmentosa Market, by End-use

  • 8.1. Introduction
  • 8.2. Homecare
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Retinitis Pigmentosa Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Retinitis Pigmentosa Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Retinitis Pigmentosa Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. jCyte's jCell Therapy Enters Phase 3 Trials for Retinitis Pigmentosa
    • 12.3.2. Janssen Acquires Rights to Pioneering XLRP Gene Therapy from MeiraGTx, Catalyzing Advancements in Retinal Diseases
    • 12.3.3. The RD Fund Backs NVasc's Breakthrough in Retinal Therapeutics
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 4D Molecular Therapeutics, Inc.
  • 2. Astellas Pharma Inc.
  • 3. Beacon Therapeutics Limited
  • 4. BIOGEN INC.
  • 5. Clino Corporation
  • 6. Coave Therapeutics SA
  • 7. Editas Medicine, Inc.
  • 8. GENSIGHT BIOLOGICS
  • 9. Genethon
  • 10. Johnson & Johnson Services, Inc.
  • 11. MeiraGTx Holdings PLC
  • 12. Mimetogen Pharmaceuticals
  • 13. Nacuity Pharmaceuticals, Inc.
  • 14. Novartis AG
  • 15. Orphagen Pharmaceuticals, Inc.
  • 16. Oxford Biomedica PLC
  • 17. Precision BioSciences, Inc.
  • 18. ProQR Therapeutics N.V.
  • 19. Sanofi S.A.
  • 20. Santen Pharmaceutical Co., Ltd.
  • 21. Spark Therapeutics, Inc.
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. The Wyanoke Group

LIST OF FIGURES

  • FIGURE 1. RETINITIS PIGMENTOSA MARKET RESEARCH PROCESS
  • FIGURE 2. RETINITIS PIGMENTOSA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RETINITIS PIGMENTOSA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RETINITIS PIGMENTOSA MARKET DYNAMICS
  • TABLE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY X-LINKED RETINITIS PIGMENTOSA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2023